Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I2R-MC-BIAM: LY2605541 vs insulin glargine in type 2 diabetes
2011-001254-29Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2011
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of insulin peglispro in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to 26 weeks (non-inferiority vs insulin glargine). Started Oct 2011; status: completed.
02
Drugs
insulin peglispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-001254-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001254-29.